Lansheng Biopharmaceutical

Lansheng Biopharma is a clinical-stage biopharmaceutical company headquartered in Taizhou, China, specializing in the discovery and development of innovative small molecule and biologic drugs. The company's primary therapeutic focus is on oncology and autoimmune diseases, with a pipeline designed to address significant unmet medical needs. Its lead candidate, LS-007, is a selective CDK4/6 inhibitor currently undergoing clinical evaluation for the treatment of advanced breast cancer and other solid tumors. Lansheng operates integrated research, development, and manufacturing facilities within the China Medical City (CMC) hub. By leveraging its proprietary technology platforms, the company aims to accelerate the delivery of high-quality therapeutic solutions to the global market.